IE
IMUC

Israel Englander’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Israel Englander’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-376,944
Closed -$94K – 4474
2018
Q1 		$94K Buy
+376,944
New +$104K ﹤0.01% 3487
2014
Q1 		– Sell
-264
Closed -$10K – 4317
2013
Q4 		$10K Sell
264
-235
-47% -$22.3K ﹤0.01% 3404
2013
Q3 		$51K Buy
+499
New +$54.8K ﹤0.01% 3224

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Israel Englander's IMUC Position: Q2 2018 in Review

Israel Englander sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2018, closing a stake of 376,944 shares — an estimated $94K sold.

Israel Englander first reported a position in IMUC in Q3 2013 and held it in 3 quarters. The position peaked at $94K in Q1 2018. 20 funds tracked by Wall St. Rank hold IMUC as of Q2 2018.

  • Israel Englander reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2018 after selling out during the quarter.
  • Israel Englander sold 376,944 ImmunoCellular Therapeutics, Ltd. shares in Q2 2018, an estimated $94K.
  • Israel Englander first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 3 quarters.
  • Israel Englander's ImmunoCellular Therapeutics, Ltd. position peaked at $94K in Q1 2018.
  • 20 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2018.

Based on Millennium Management's 13F filing for Q2 2018, filed 14 Aug 2018.